Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) July 27, 2021
LEXARIA BIOSCIENCE CORP.
(Exact name of registrant as specified in its charter)
Nevada
000-52138
20-2000871
(State or other jurisdiction
of incorporation)
(Commission
File Number)
(IRS Employer
Identification No.)
100 – 740 McCurdy Road, Kelowna, BC Canada
V1X 2P7
(Address of principal executive offices)
(Zip Code)
Registrant’s telephone number, including area code (250) 765-6424
_____________________________________________
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, par value $0.001 per share
Warrants to Purchase Common Stock
LEXX
LEXXW
The Nasdaq Capital Market
The Nasdaq Capital Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 8.01
Other Events
On July 27, 2021, Lexaria Bioscience Corp. (“Lexaria”) announced the additional expansion of its intellectual property portfolio with the allowance of its second patent in Japan. The patent is titled “Food and Beverage Compositions Infused with Lipophilic Active Agents and Methods of Use Thereof” and becomes the 21st patent granted to Lexaria and the 17th patent granted in Lexaria’s first patent family.
On July 28, 2021 Lexaria announced that its DehydraTECHTM technology was now incorporated into consumer brands available for sale in over 7,000 stores across the US, including Albertsons, Vons, Hudson News and Safeway.
On July 29, 2021 Lexaria issued partial results from human clinical study HYPER-H21-1 evaluating DehydraTECHTM-processed cannabidiol for potential application against hypertension. See Exhibit 99.1.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
LEXARIA BIOSCIENCE CORP.
/s/ Chris Bunka
Chris Bunka
CEO, Principal Executive Officer
Date: July 30, 2021
- 3 -
We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.
